Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 4523673, 12 pages
https://doi.org/10.1155/2017/4523673
Research Article

Experimental and Clinical Applications of Chamaecyparis obtusa Extracts in Dry Eye Disease

1The Affiliated Eye Hospital, Wenzhou Medical University, Wenzhou, China
2Department of Ophthalmology and Center for Creative Biomedical Scientists, Chonnam National University, Gwangju, Republic of Korea
3Balgeun Eye Clinic 21, Gwangju, Republic of Korea
4College of Veterinary Medicine and BK 21 PLUS Project Team, Chonnam National University, Gwangju, Republic of Korea
5Business Supporting Team, Center for Nano Bio Research, Jangseong, Jeonnam, Republic of Korea
6Jeonnam Forest Resource Research Institute, Naju, Jeonnam, Republic of Korea

Correspondence should be addressed to Kyung Chul Yoon; rk.ca.unj@nooyck

Received 28 February 2017; Revised 22 September 2017; Accepted 27 September 2017; Published 26 December 2017

Academic Editor: Steven McAnulty

Copyright © 2017 Lian Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients. Methods. 0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability, and production of antioxidative enzymes, and reactive oxygen species (ROS) were assessed. Afterwards, CO extracts or balanced salt solution (BSS) was applied in EDE. Clinical and experimental parameters were measured at 7 days after treatment. In addition, DED patients were randomly assigned to wear either an eye mask containing CO extracts or a placebo. Clinical parameters were evaluated. Results. The viability of HCE cells and antioxidative enzyme expression significantly improved after treatment with 0.1% CO extracts. Mice treated with 0.1% CO extracts showed significant improvement in clinical parameters. During the trial, the clinical parameters significantly improved in the treatment group at 4 weeks after application. Conclusions. 0.1% CO extracts could promote the expression of antioxidative proteins and ROS production. In addition, an eye mask containing CO extracts could improve DED clinical parameters. These suggest that CO extracts may be useful as an adjunctive option for the DED treatment.